Ετικέτες

Κυριακή 6 Φεβρουαρίου 2022

Cephalic vein transposition in head-and-neck reconstruction

xlomafota13 shared this article with you from Inoreader

1-s2.0-S1879729621X00129-cov150h.gif

Publication date: Available online 4 February 2022

Source: European Annals of Otorhinolaryngology, Head and Neck Diseases

Author(s): B. Benbassat, F. Cros, A. Dupret-Bories, T. Meresse

View on the web

Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

Transl Cancer Res. 2021 Nov;10(11):4914-4928. doi: 10.21037/tcr-21-2417.

ABSTRACT

BACKGROUND: Differentiated thyroid cancer (DTC) is the most common thyroid tumor, and the cells of DTC patients can lose the ability to differentiate in their natural state or during treatment and develop radioiodine-refractory DTC (RAI-R DTC), resulting in increased malignancy. Monocarboxylate transporter-1 (MCT1 ) is positively correlated with the level of malignant of various tumo rs, and its expression in RAI-R DTC cells is correlated with their biological cell traits.

METHODS: Data from 14 iodine-refractory thyroid carcinoma patients were collected, and the effective radioiodine treatment group was used as the control group. The expression of MCT1 in iodine-refractory thyroid carcinoma and its effect on biological behaviors was observed and the molecular mechanism underlying RAI-R DTC was investigated to determine the cause of the loss of sensitivity of DTC to radioactive iodine using Immunohistochemical staining, Western blot, transwell assay, wound healing assay, flow cytogram assay.

RESULTS: Compared to radioiodine-sensitive DTC (RAI-DTC), which was responded to iodine treatment, MCT1 was highly expressed in RAI-R DTC cells. The overexpression or inhibition of MCT1 altered the biological characteristics of papillary thyroid carcinoma (TPC-1) cells. The overexpression of MCT1< /i> in TPC-1 cells increased the invasive, proliferative, and migratory abilities of the cells. Conversely, the downregulation of MCT1 decreased the invasive, proliferative and migratory abilities of the cells.

CONCLUSIONS: The expression of MCT1 was enhanced in RAI-R DTC cells. MCT1 appears to be closely related to the invasive metastasis of RAI-R DTC cells, and it may be the cause of the loss of the iodine uptake ability of RAI-R DTC.

PMID:35116343 | PMC:PMC8797869 | DOI:10.21037/tcr-21-2417

View on the web

New approaches for patients with advanced radioiodine-refractory thyroid cancer

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

World J Clin Oncol. 2022 Jan 24;13(1):9-27. doi: 10.5306/wjco.v13.i1.9.

ABSTRACT

The cumulative evidence over the past decades has shown that the incidence of differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of patients with DTC exhibit recurrent or metastatic disease, and about two-thirds of the latter will be defined as refractory to radioactive iodine (RAIR) treatment. Since this condition implies 10-year survival rates less than 10% after de tection, using available treatments, such as systemic and targeted therapies, have become increasingly relevant. The initiation of these treatments aims to reach stabilization, tumor volume reduction, and/or symptom improvement and it should be decided by highly specialized endocrinologists/oncologists on the basis of patient's features. Considering that despite enlarged progression-free survival was proven, multikinase inhibitors remain non-curative, their benefits last for a limited time and the side effects potentially cause harm and quality of life reduction. In this context, molecular testing of cancer cells provides a promising spectrum of targeted therapies that offer increased compatibility with individual patient needs by improving efficacy, progression free survival, overall survival and adverse events profile. This review article aims to provide a summary of the current therapeutic strategies in advanced RAIR-DTC, including approved target therapies as well as those for < i>off-label use, RAI resensitization agents, and immunotherapy.

PMID:35116229 | PMC:PMC8790300 | DOI:10.5306/wjco.v13.i1.9

View on the web

A comprehensive analysis of intratumor microbiome in head and neck squamous cell carcinoma

xlomafota13 shared this article with you from Inoreader

Eur Arch Otorhinolaryngol. 2022 Feb 5. doi: 10.1007/s00405-022-07284-z. Online ahead of print.

ABSTRACT

PURPOSE: Human microbiome has been considered as the second genome of our body. The intratissue/intratumor microbiome analysis is a relatively new field and deserves more attention. In this study, we conducted a comprehensive analysis of microbiome signatures of head and neck squamous cell carcinoma (HNSC).

METHODS: The intratumor microbiome profiling and clinicopathological information about a total of 177 HNSC samples, including 155 tumors and 22 adjacent normal tissues, were obtained from The Cancer Microbiome Atlas (TCMA) and The Cancer Genome Atlas (TCGA) databases. We identified the microbes that differed between tumors and normal tissues, and assessed their utility values as diagnostic biomarkers. The microbiome signatures under different conditions of clinicopathological parameters were also analyzed.

RESULTS: The intratissue microbiome profiles differed between tumor and normal samples of HNSC. The composition of four, six, and six microbes changed in tumors compared to normal tissues at the phylum, order, and genus levels, respectively (P < 0.05). Eight of the differential microbes performed well in distinguishing tumors from normal tissues (AUC > 0.7, P ≤ 0.001). The microbiome signature was found to be associated with tumor clinicopathological characteristics such as host-gender, host-age, tumor stage, and neoplasm histologic grade.

CONCLUSION: Overall, our results revealed an intratissue microbiome signature of HNSC. We concluded that the intratumor microbiome signature may also reflect human biology in both healthy and disease status, and provide novel perspective for microbiota research about their roles in tumors.

PMID:35122129 | DOI:10.1007/s00405-022-07284-z

View on the web

Mutations within the putative protease domain of the human FAM111B gene may predict disease severity and poor prognosis: A review of POIKTMP cases

xlomafota13 shared this article with you from Inoreader

Abstract

Mutations in the human FAM111B gene are associated with a rare, hereditary multi-systemic fibrosing disease, POIKTMP. To date, there are ten POIKTMP-associated FAM111B gene mutations reported in thirty-six patients from five families globally.

To investigate the clinical significance of these mutations, we summarized individual cases by clinical features and position of the reported FAM111B gene mutations as those within and outside the putative protease domain (MWPPD and MOPPD, respectively).

MWPPD cases had more clinical manifestations than MOPPD (25 versus 18). Although the most common clinical features of poikiloderma, alopecia, and hypohidrosis overall occurred in 94%, 86%, and 75% of all cases with no significant differences between the MOPPD and MWPPD group, less common features included life-threatening (pulmonary fibrosis 47 % vs. 13 %; liver abnormalities specifically cirrhosis 26 % vs. 7 %) and physically disabling conditions (myopathy 53% vs. 20%; tendon contracture 55% vs. 7%) were more common in MWPPD cases. Similarly, the only 2 cases of POIKTMP with fatal pancreatic cancers were both only in the MWPPD group.

This review thus suggests that mutations within the putative protease domain of the FAM111B protein are associated with a broader range of clinical features and may predict increased POIKTMP severity and a poorer prognosis.

View on the web

Hybrid Renal Cortical Imaging with Single Photon Emission Computerized Tomography/Computed Tomography in a Pediatric Patient with Severe Caudal Regression Syndrome

xlomafota13 shared this article with you from Inoreader

Mol Imaging Radionucl Ther. 2022 Feb 2;31(1):69-71. doi: 10.4274/mirt.galenos.2020.84755.

ABSTRACT

Caudal regression syndrome (CRS) or sacral agenesis is a rarely seen malformation with a varying degree of structural abnormalities, including multiorgan system dysfunctions, reported with higher incidence among children of mothers with diabetes, as in this case. Spinal anomalies can range from coccyx hemiagenesis to the total absence of lower lumbar vertebrae and sacrum in most severe cases. Herein, we have presented a 9-year-old patient with CRS who had renal failure. Technetium-99m dimercaptosuccinic acid renal scintigraphy revealed bilaterally non-functioning kidneys with no renal cortical uptake. Renal anomalies in CRS with vertebral, anorectal, cardiac, trachea-esophageal, renal, and limb anomalies association include one-sided renal agenesis, multicystic dysplastic kidneys, and ureter duplications.

PMID:35114757 | DOI:10.4274/mirt.galenos.2020.84755

View on the web

Αναζήτηση αυτού του ιστολογίου